2PU.F PULMATRIX INC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
1.12 EUR
Close of Nov 11, 2026
0.8690 4.10
Market cap
EUR 4.10M
P/E
-
P/B
2.87x
ROE
-172.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2PU.F undervalued?

Graham number

The Graham number of PULMATRIX INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PULMATRIX INC. DL-0001 fundamental analysis

No fundamental analysis for PULMATRIX INC. DL-0001 yet.

PULMATRIX INC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PULMATRIX INC. DL-0001

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed …

Full company profile